HaloVax is a pre-clinical biotech company focused on bringing our Self-Assembling Vaccine (SAV) to patients at risk for COVID-19 infection. We believe that our vaccine could be particularly effective and improve patient outcomes by engaging the immune system to identify and attack this pandemic infectious agent.
This technology has initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease. This was done with the support of the DoD. These same principles are being applied to developing a vaccine against the pandemic coronavirus, known as COVID-19
The SAV program has intellectual property surrounding composition of matter. Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts which used classic adjuvants like alum, etc. The vaccine is >90% HSP70 and Aviden. Neoantigens are then incorporated to customize the vaccine.
We believe that the VaxCelerate technology has the potential to provide a differentiated approach to a COVID-19 vaccine.